Loading...
Market
Completion of J&J Acquisition of Proteologix by June 2024?
5
Resolution / Starting Odds
Yes • 50%
No • 50%
SEC filings or Johnson & Johnson press releases
Story
Johnson & Johnson to Acquire Proteologix for $850 Million to Boost Immunology Portfolio
May 16, 2024, 12:25 PM
On May 16, Johnson & Johnson announced that it will acquire privately held, stealthy start-up Proteologix for $850 million in cash, with the potential for additional milestone payments. The acquisition aims to bolster Johnson & Johnson's position in the treatment of atopic dermatitis and other immunologic disorders. Proteologix brings a pipeline of bispecific antibodies, including a phase 1-ready TSLP/IL13 bispecific and experimental treatments for asthma and atopic dermatitis. This acquisition, which includes dual-targeting antibody drugs, is part of Johnson & Johnson's strategy to expand its immunology portfolio and is the latest M&A deal involving molecules addressing TSLP.
View original story
Similar markets
Approved • 50%
Not Approved • 50%
Yes • 50%
No • 50%
Successful • 33%
Partially successful • 34%
Unsuccessful • 33%
Significant gain in market share • 33%
Moderate gain in market share • 34%
No significant change in market share • 33%
